GET DAILY SIGNALSBiogen (BIIB) Posts +11% Revenue Growth in Q3 as Growth Portfolio Accelerates
Key Takeaways
- Biogen reported total revenue of $2.80 billion for the third quarter, up 11% year over year and above consensus estimates of roughly $2.64 billion.
- Adjusted (non-GAAP) earnings per share came in at $2.62, comfortably beating analyst expectations of about $2.02, while GAAP results slipped to a net loss of $0.14 per share on transaction-related charges.
- The Growth Portfolio generated $1.26 billion in revenue, up 49% year over year, and now represents roughly 63% of core pharmaceutical revenue.
- Biogen raised the lower end of its full-year 2026 adjusted earnings per share guidance to a range of $12.20 to $13.00, reflecting business strength and favorable Apellis-related dilution.
- Multiple sclerosis product revenue declined 13% to $919 million, underscoring continued competitive pressure on the company's legacy franchise.
- For more information on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
- Discover additional market opportunities by exploring Trending AI Robots.
Why the Quarter Matters
Biogen's third-quarter results mark a pivotal checkpoint in the company's ongoing effort to pivot away from its aging multiple sclerosis franchise and toward a diversified growth portfolio spanning neurology, rare disease, and immunology. This quarter included the first full three-month contribution from SYFOVRE and EMPAVELI, acquired through the Apellis transaction completed in May 2026. Investors have been closely watching whether these newer products can offset persistent declines in legacy treatments such as TECFIDERA and VUMERITY. The report also carried heightened significance because of Biogen's near-term clinical catalysts, with pivotal late-stage readouts expected in the coming months. A return to double-digit revenue growth signals that the strategic transition is gaining traction, even as elevated research spending and acquisition-related charges weigh on reported profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Numbers
Biogen posted third-quarter total revenue of $2.80 billion, an 11% increase from $2.53 billion in the prior-year period and ahead of analyst forecasts. Adjusted earnings per share (EPS) reached $2.62, exceeding the consensus estimate of roughly $2.02, though it declined from $4.81 a year earlier. On a generally accepted accounting principles (GAAP) basis, the company recorded a net loss of $20.6 million, or $0.14 per share, compared with net income of $466.5 million, or $3.17 per share, a year ago. The swing to a GAAP loss primarily reflected $284 million in acquired in-process research and development (IPR&D) charges tied to the RayThera acquisition, along with amortization and restructuring costs.
The Growth Portfolio delivered $1.26 billion in revenue, up 49% year over year. SPINRAZA rose 23% to $461 million, LEQEMBI climbed 67% to $202 million, and SKYCLARYS advanced 34% to $178 million. The newly acquired Apellis products contributed a combined $243 million, with SYFOVRE recording $191 million and EMPAVELI $52 million. Rare disease revenue increased 27% to $676 million, while multiple sclerosis product revenue fell 13% to $919 million. Biogen also raised the lower end of its full-year 2026 adjusted EPS guidance to $12.20, maintaining the upper end at $13.00, and reaffirmed expectations for mid-single-digit full-year revenue growth.
Market Reaction and Sentiment
Sentiment around Biogen's report centered on the strength of the top-line beat and the upward revision to full-year earnings guidance, which suggested that the company's growth portfolio is scaling faster than anticipated. The first full-quarter contribution from SYFOVRE and EMPAVELI reinforced confidence that the Apellis integration is progressing well, with management indicating the deal is now roughly neutral on an operating basis. Still, the GAAP loss and a 13% decline in the legacy multiple sclerosis franchise tempered some enthusiasm, reminding investors that the company's transformation is not yet complete. Looking ahead, market attention is shifting to a series of late-stage clinical readouts expected over the next several months, which could act as more significant catalysts for the stock than the quarterly figures themselves. From what I see, this balance of progress and lingering challenges is worth monitoring closely.
Forward Outlook and Key Factors
Biogen's near-term narrative now hinges on its registrational readout cycle. The company expects to announce top-line data from the TOPAZ-1 and TOPAZ-2 Phase 3 studies of litifilimab in systemic lupus erythematosus (SLE) in the first half of December 2026. Positive results could materially expand Biogen's immunology franchise and reinforce its diversification strategy.
Beyond that, additional Phase 3 readouts are anticipated for litifilimab in cutaneous lupus erythematosus (CLE) and felzartamab in antibody-mediated rejection during the first half of 2027, followed by zorevunersen in Dravet syndrome in the third quarter of 2027. These catalysts represent a multi-year data flow that management frames as central to the company's next phase of growth.
Investors should also monitor the trajectory of LEQEMBI uptake, the normalization of SPINRAZA's high-dose conversion tailwind, and the company's ability to stabilize the multiple sclerosis business. Rising research and development expenses, combined with a net debt position of roughly $6.4 billion, remain factors worth tracking as Biogen balances pipeline investment against profitability.
Using AI Tools in My Research
I often rely on Tickeron’s AI Screener when evaluating names like BIIB alongside peers in biotech. It helps me quickly scan for technical patterns, fundamentals, and performance metrics that might otherwise take hours to review manually, giving a clearer picture of where opportunities sit in the sector right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for BIIB shows an upward move is likely
BIIB's Aroon Indicator triggered a bullish signal on October 26, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 197 similar instances where the Aroon Indicator showed a similar pattern. In 121 of the 197 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 61%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BIIB as a result. In 48 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for BIIB just turned positive on October 13, 2026. Looking at past instances where BIIB's MACD turned positive, the stock continued to rise in 35 of 59 cases over the following month. The odds of a continued upward trend are 59%.
Following a +0.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 167 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
Bearish Trend Analysis
The 10-day RSI Indicator for BIIB moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 19 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
BIIB broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 7 (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.913) is normal, around the industry mean (-2.729). P/E Ratio (42.967) is within average values for comparable stocks, (20.997). Projected Growth (PEG Ratio) (2.357) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders
Industry PharmaceuticalsMajor
Advertisement